The Value of High-flow Nasal Cannula Oxygen Therapy in Treating Novel Coronavirus Pneumonia

Overview

Journal Eur J Clin Invest

Publisher Wiley

Specialty General Medicine

Date 2020 Oct 17

PMID 33068293

Citations 24

Authors

Xiao-Bao Teng

Ya Shen

Ming-Feng Han

Gang Yang

Lei Zha

Jing-Feng Shi

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate the value of high-flow nasal cannula (HNFC) oxygen therapy in treating patients with severe novel coronavirus pneumonia (COVID-19).

Methods: The clinical data of 22 patients with severe COVID-19 were collected. The heart rate (HR), respiratory rate (RR) and oxygenation index (PO /FiO ) at 0, 6, 24 and 72 hours after treatment were compared between the HFNC oxygen therapy group and the conventional oxygen therapy (COT) group. In addition, the white blood cell (WBC) count, lymphocyte (L) count, C-reactive protein (CRP) and procalcitonin (PCT) were compared before and at 72 hours after oxygen therapy treatment.

Results: The differences at 0 hours between the two groups were not statistically significant. Compared with COT group,in the HFNC oxygen therapy group, HR, RR and PaO /FiO were better at 6 hours after treatment, PaO /FiO was better at 24 and 72 hours. After 72 hours, L and CRP had improved in the HFNC oxygen therapy group compared with the COT group, but the differences in WBC and PCT were not statistically significant. The length of stay in the intensive care unit (ICU) and the total length of hospitalization was shorter in the HFNC oxygen therapy group than in the COT group.

Conclusion: Compared with COT, early application of HFNC oxygen therapy in patients with severe COVID-19 can improve oxygenation and RR, and HFNC oxygen therapy can improve the infection indexes of patients and reduce the length of stay in the ICU of patients. Therefore, it has high clinical application value.

Citing Articles

Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Patients After Esophagectomy.

Shen Y, Xu Y, Xu F, Wang X, Duan S, Chen Y Can Respir J. 2025; 2025:4691604.

PMID: 40017621 PMC: 11867717. DOI: 10.1155/carj/4691604.

High-flow nasal oxygen therapy compared with conventional oxygen therapy in hospitalised patients with respiratory illness: a systematic review and meta-analysis.

Seow D, Khor Y, Khung S, Smallwood D, Ng Y, Pascoe A BMJ Open Respir Res. 2024; 11(1).

PMID: 39009460 PMC: 11268052. DOI: 10.1136/bmjresp-2024-002342.

An Individual Barrier Enclosure Actively Removing Aerosols for Airborne Isolation: A Vacuum Tent.

Vieira F, Masy V, LaRue R, Laengert S, De Lannoy C, Rodrigues A Respir Care. 2024; 69(4):395-406.

PMID: 38538026 PMC: 11108102. DOI: 10.4187/respcare.11094.

Challenges of mesenchymal stem cells in the clinical treatment of COVID-19.

Li L, Zhang X, Wu Y, Xing C, Du H Cell Tissue Res. 2024; 396(3):293-312.

PMID: 38512548 DOI: 10.1007/s00441-024-03881-y.

Comparison between high-flow nasal cannula and conventional oxygen therapy in COVID-19 patients: a systematic review and meta-analysis.

Wang J, Peng Y, Dai B, Hou H, Zhao H, Wang W Ther Adv Respir Dis. 2024; 18:17534666231225323.

PMID: 38230522 PMC: 10798115. DOI: 10.1177/17534666231225323.

References

Vargas F, Saint-Leger M, Boyer A, Bui N, Hilbert G . Physiologic Effects of High-Flow Nasal Cannula Oxygen in Critical Care Subjects. Respir Care. 2015; 60(10):1369-76. DOI: 10.4187/respcare.03814. View

Frizzola M, Miller T, Rodriguez M, Zhu Y, Rojas J, Hesek A . High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol. 2010; 46(1):67-74. PMC: 3332105. DOI: 10.1002/ppul.21326. View

Peters S, Holets S, Gay P . High-flow nasal cannula therapy in do-not-intubate patients with hypoxemic respiratory distress. Respir Care. 2012; 58(4):597-600. DOI: 10.4187/respcare.01887. View

Cuquemelle E, Pham T, Papon J, Louis B, Danin P, Brochard L . Heated and humidified high-flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Respir Care. 2012; 57(10):1571-7. DOI: 10.4187/respcare.01681. View

Dysart K, Miller T, Wolfson M, Shaffer T . Research in high flow therapy: mechanisms of action. Respir Med. 2009; 103(10):1400-5. DOI: 10.1016/j.rmed.2009.04.007. View

Groves N, Tobin A . High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care. 2007; 20(4):126-31. DOI: 10.1016/j.aucc.2007.08.001. View

Teng X, Shen Y, Han M, Yang G, Zha L, Shi J . The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia. Eur J Clin Invest. 2020; 51(3):e13435. PMC: 7645937. DOI: 10.1111/eci.13435. View

Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R . Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014; 14:66. PMC: 4126617. DOI: 10.1186/1471-2253-14-66. View

Corley A, Caruana L, Barnett A, Tronstad O, Fraser J . Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011; 107(6):998-1004. DOI: 10.1093/bja/aer265. View

10.

Frat J, Brugiere B, Ragot S, Chatellier D, Veinstein A, Goudet V . Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. Respir Care. 2014; 60(2):170-8. DOI: 10.4187/respcare.03075. View

11.

Frat J, Thille A, Mercat A, Girault C, Ragot S, Perbet S . High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015; 372(23):2185-96. DOI: 10.1056/NEJMoa1503326. View